Selected publications:
- An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.
Elife. 2018 Jul 30; 7.
- Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers.
Nature genetics. 2016; 48(2):176-82.
- Targeted genomic rearrangements using CRISPR/Cas technology.
Nature communications. 2014; 5:3728.
- Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.
PNAS. 2014; 111(32):E3316-24.
- Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
PNAS. 2011; 108(42):17432-7.
*equal contribution
Other publications:
- Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor.
Cancer discovery. 2018; 8(1):108-125.
- MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.
Cancer research. 2017; 77(16):4498-4505.
- BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.
Oncotarget. 2016; 7(19):26926-34.
- MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.
Cancer cell. 2014; 26(2):262-72.
- A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.
PloS one. 2014; 9(1):e87361.